GW Pharmaceuticals PLC (GWPH)

107.93
1.60 1.50
NASDAQ : Health Care
Prev Close 106.31
Open 110.50
Day Low/High 106.65 / 111.95
52 Wk Low/High 35.83 / 120.99
Volume 352.92K
Avg Volume 284.60K
Exchange NASDAQ
Shares Outstanding 25.33M
Market Cap 2.73B
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More

Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More

Here are Friday's top research calls, including upgrades for Chemours, Incyte and Toyota, and new coverage of Visteon.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SOHO, TM, VEC, WWW Downgrades: BID, FF, GWPH Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Bull Market Reaching Mature Stage, Dow Could Dip to 19,000

Bull Market Reaching Mature Stage, Dow Could Dip to 19,000

The rallies in the stock market could be indicators of irrational exuberance and are not sustainable because of anemic growth, low unemployment and high valuations in equities.

Analysts Actions -- Costco, McDonald's, GW Pharma, Kinder Morgan and More

Analysts Actions -- Costco, McDonald's, GW Pharma, Kinder Morgan and More

Here are Friday's top research calls, including an upgrade for Costco and new coverage of McDonald's, GW Pharma and Kinder Morgan.

Happy 420! A Roundup of Investing Advice in the Green Gold Rush

Happy 420! A Roundup of Investing Advice in the Green Gold Rush

As more states legalize, your portfolio could smoke the competition.

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex® (cannabidiol) Data Released By The American Academy Of Neurology

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex® (cannabidiol) Data Released By The American Academy Of Neurology

More Detailed Poster Presentation Scheduled for April 25, 2017 at AAN Annual Meeting

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences To Present Data On Epidiolex® (cannabidiol) At The 2017 American Academy Of Neurology Annual Meeting

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences To Present Data On Epidiolex® (cannabidiol) At The 2017 American Academy Of Neurology Annual Meeting

- New Phase 3 Data in Lennox-Gastaut Syndrome Selected for Inclusion in the Emerging Science Program -

Collect Smokin' Hot Profits From This Marijuana Biotech

Collect Smokin' Hot Profits From This Marijuana Biotech

This innovative biotech offers investors an intriguing play on the medical marijuana business.

Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs

Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs

In the first quarter of the year we've seen some high-profile IPOs. But they're not all created equal. Here's what investors should keep an eye out for ... and avoid.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRK, AXTA, DFT, GWPH, LBRDK, LBTYA, RPM Downgrades: CIEN, CRNT, IMO, SUNW, TG, TRIB, USCR Initiations: FBIO Read on to get TheStreet Quant Ratings' detailed report:

Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)

Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)

This economy is finally strong enough that a rate hike is natural and necessary, says Jim Cramer.

Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round

Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer's bullish on Burlington Stores, Ross Stores and TJX Companies.

Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks

Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks

The woes of anti-marijuana Attorney General Jeff Sessions are fueling speculative pot stock buying. But you should avoid these two high flying small fry.

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.

3 Reasons Why Marijuana's Momentum Is Stronger than Ever

3 Reasons Why Marijuana's Momentum Is Stronger than Ever

We talk with an industry expert about the outlook of the marijuana industry.

GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer

GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer

The applications for the company's proprietary treatments seem endless. How can investors get in, and what are the alternative pot profit-makers?

You Can Also Get High on Marijuana Stocks -- Here's How

You Can Also Get High on Marijuana Stocks -- Here's How

Everyone else is doing it.